**Table E4. Data abstraction of randomized controlled trials of NSAIDs**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Country Number of Centers and Setting** | **Inclusion Criteria** | **Number Randomized, Analyzed Attrition** | **Intervention** | **Study Participants** | **Duration of Pain (acute, subacute, chronic)** |
| Herrmann, 2009 | GermanyMulticenterOutpatient | 18-70 years, sciatica orlumbosciatica with onset within the last 72 hours with any previous attacks had to be resolved at least 3 months earlier. | Randomized: 171Analyzed: 171Attrition: 0 | A: Lornoxicam 8mg tablets,with 16 mg loading dose on day 1, then 8mg after 8 hours; 8 mg twice per day on days 2-4; 8 mg on day 5B: Diclofenac: 50 mg twice per day on days 1 and 5;50mg three times per day on days 2-4.C: Placebo capsules in lornoxicamor diclofenac blister packsDay 5 treatment was optional | Mean age: 51.8 vs. 48.9 vs.48.4Gender, male: 56% vs.53% vs. 58%Race, Caucasian: 91% vs.93% vs. 98%Pain etiology: Sciatica or lumbosciatica | Acute pain, totalduration of previouslow back pain: 53.8 vs.44.1 vs. 53.9 months |
| Majchrzycki, 2014 | PolandSingle centerOutpatient clinic | 40-60 years old, Painlasting longer than 7 weeks, VAS1 and VAS2 scores ≥25mm of 100mm, noNSAID or strong analgesic therapy during the last 3 months | Randomized: 59Analyzed: 54Attrition: 5 | A. Deep tissue massage +NSAID (n=26)B. Deep tissue massage(n=28) | Mean age: 50.8 vs. 52.6Gender, female: 13/26 vs.13/28Race: NRChronic pain: 100% Baseline pain: NR Baseline function: NR QOL: NR | Subacute duration,weeks: 11.9±3.9 vs.10.8±2.4 |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Duration of****Followup** | **Results** | **Adverse Events****Including Withdrawals** | **Funding****Source** | **Quality** |
| Herrmann, 2009 | 5 days | A vs. B vs. CPain intensity difference, mm:3 hours: -21.0 vs. -18.7 vs. -15.3, p ≤0.05 for A vs. C4 hours: -22.0 vs. -21.5 vs. -14.8, p ≤0.05 for A vs. C6 hours: -20.5 vs. -22.4 vs. -14.9, p ≤0.05 for A vs. C8 hours: -22.0 vs. -24.1 vs. -13.7, p ≤0.05 for A vs. CSum of time-weighted pain intensity difference, mm x minute:0-4 hours: -4020 vs. -3879 vs. -2901, p ≤0.05 for A vs. C0-6 hours: -6486 vs. -6358 vs. -4713, p ≤0.05 for A vs. C0-8 hours: -9125 vs. -8833 vs. -6257, p ≤0.05 for A vs. CPain Relief (mm):3 hours: 30.1 vs. 30.8 vs. 26.64 hours: 31.7 vs. 33.9 vs. 26.66 hours: 31.1 vs. 34.3 vs. 26.18 hours: 31.9 vs. 35.6 vs. 23.9, p ≤0.05 for A vs. CPeak pain intensity difference, A vs. C: -27.9 mm vs. -19.9 mm, p=0.01Time to peak pain intensity difference, A vs. C: 243 vs. 240 minutes, no differencePeak pain relief, A vs. C : 38.0 mm vs. 31.1 mm, p=0.05Time to peak pain relief: no difference Start of peak pain relief: no difference End of peak pain relief: no differenceDuration of peak pain relief: no difference | A vs. B vs. CWithdrawals: 4 vs. 2 vs. 1Withdrawals due to AEs: 2 vs. 1 vs. 0Serious AEs: 0 vs. 2 vs. 0Nonserious AEs: 11 vs. 7 vs. 7 | NycomedPharma Austria, Merckle GmbH Ulm, Germany | Fair |
| Majchrzycki, 2014 | 2 weeks | Difference scores, no significantly different results between groups on:Roland-Morris questionnaire: 21.2 vs. 16.1Oswestry disability index: 24.7 vs. 19.6VAS1: pain intensity during resting: 16.5 vs. 13.9VAS2: pain intensity during motion: 3.2 vs. 3.4VAS3: pain intensity during mobility of the aching area of the spine: 4.8 vs. 8.2 | Withdrawals: 3 vs. 2Withdrawals due to AEs: NRSerious AEs: NR Nonserious AEs: NR | Not reported | Fair |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Country Number of Centers and Setting** | **Inclusion Criteria** | **Number Randomized, Analyzed Attrition** | **Intervention** | **Study Participants** | **Duration of Pain (acute, subacute, chronic)** |
| Shirado, 2010 | JapanMulticenter Orthopedic surgeon clinics | Age 20-64, nonspecificchronic low back pain of more than 3 months duration | Randomized: 201Analyzed: 193Attrition: 8 | A: NSAIDs: loxoprofensodium, 60 mg tablet 3 times daily; diclofenac sodium, 25 mg tablet 3 times daily; or zaltoprofen, 80 mg tablet 3 times dailyB: Exercise: medical professionals at each clinic gave instruction of the exercise. 2 types of exercise: trunk strengthening and stretching. 2 sets of 10 repetitions of each exercise per day were encouraged. | Mean Age: 42.5 vs. 42.0Female: 59% vs. 52% Race: NRPain type: All chronic painBaseline pain:VAS (0-10): 3.8 vs. 3.5QOL scores:RDQ (0-24): 3.7 vs. 3.0JLEQ score (0-120): 21.8 vs. 20.5 | ≥ Subacute duration,details not reported |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Author, Year** | **Duration of****Followup** | **Results** | **Adverse Events****Including Withdrawals** | **Funding****Source** | **Quality** |
| Shirado, 2010 | 12 months | Baseline to 8 week change ratio:Pain: VAS: -0.35 vs. -0.44, p=0.332Function: Finger-floor distance: 0.00 vs. -0.09, p=0.112RDQ: -0.47 vs. -0.72, p=0.023JLEQ: -0.44 vs. -0.58, p=0.021 | NR | No commercialsponsor | Good |

**Please see Appendix C. Included Studies for full study references.**